Study to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Rosuvastatin

A Multi-center, Randomized, Double-blind, Parellel Phase III Clinical Trial to Evaluate the Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin in Patients With Dyslipidemia and Hypertension

To evaluate efficacy and safety of co-administrated temisartan/amlodipine and rosuvastatin in subjects with dyslipidemia with hypertension.

Inclusion Criteria:

• Dyslipidemia with hypertesion
• msSBP < 180 mmHg
• msDBP < 110 mmHg
• LDL-C ≤ 250 mg/dL
• Triglycerides < 400 mg/dL

Exclusion Criteria:

• At Visit 3, BP difference SBP ≥20mmHg or DBP ≥10mmHg
• CK normal range ≥ 2 times
• Uncontrolled primary hypothyroidism(TSH normal range ≥ 1.5 times)
• AST or ALT ≥ 2 times
• Uncontrolled diabetes mellitus (HbA1c≥9%)
• CLcr < 30 mL/min/1.73m^2
• K > 5.5 mEq/L
• Other exclusion applied